Research Summary: Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) is a low-grade B-cell malignancy. Since the introduction of targeted therapies directed at Bruton tyrosine kinase (BTK) and the B-cell lymphoma 2 (BCL2) protein, CLL outcomes have improved. Patients with CLL were historically treated with chemo-immunotherapy...
Read MoreResearch Summary: Traditionally, the gold standard treatment option for patients with cisplatin-eligible clinically localized muscle invasive bladder cancer (MIBC) has been cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) with urinary diversion. However, more recently, immune checkpoint inhibitors (ICIs) have been introduced as an...
Read MoreResearch Summary: For patients with bacillus Calmette-Guérin (BCG)–naïve, high-risk non-muscle invasive bladder cancer (NMIBC), the standard of care is transurethral resection of bladder tumor (TURBT) followed by BCG therapy. However, early recurrence rates remain high, and patients with early recurrence and high-risk NMIBC face an...
Read MoreResearch Summary: Many estrogen receptor–positive (ER+), human epidermal growth factor receptor 2–negative (HER2–) breast tumors develop resistance to aromatase inhibitors (AIs) alone or in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. However, the capacity for selective ER degraders (SERDs) to induce ER alpha degradation...
Read MoreResearch Summary: Approved by the United States Food and Drug Administration and the European Commission to treat relapsed/refractory multiple myeloma (RRMM) after 1 or more previous lines of therapy, ciltacabtagene autoleucel (cilta-cel) is a B-cell maturation antigen-directed chimeric antigen receptor T-cell (CAR T) therapy. Prior...
Read MoreResearch Summary: Muscle invasive bladder cancer (MIBC) is an aggressive subtype of bladder cancer that invades the musculature of the bladder wall. Current standard treatment involves neoadjuvant chemotherapy followed by radical cystectomy, but MIBC carries a high risk of recurrence, with about half of patients...
Read MoreResearch Summary: Unresectable, stage III non-small cell lung cancer (NSCLC) is treated with concurrent chemoradiotherapy (cCRT) followed by durvalumab for up to 12 months, which improves progression-free survival (PFS) and overall survival (OS) compared to cCRT alone. However, many patients receive sequential chemoradiotherapy (sCRT) rather...
Read MoreResearch Summary: KRAS G12C mutations occur in a substantial subset of advanced non-small cell lung cancer (NSCLC), and current first-line standards based on immune checkpoint inhibitors (ICIs), with or without chemotherapy, yield suboptimal long-term outcomes. Olomorasib is an orally bioavailable, highly selective KRAS G12C inhibitor...
Read More
Dr. Samuel Klempner reviews key data from the MATTERHORN trial,...
Read More
Dr. Galsky discusses unmet needs for patients with high-risk non-muscle...
Read More
Dr. Gautam Jayram highlights how adding durvalumab to standard gemcitabine–cisplatin...
Read More
Dr. Haley Ellis discusses efficacy data from the TOPAZ-1 clinical...
Read More
Stephanie Gregory, MS, FNP-C, BMTCN, and Jacob Bartlett, PA-C, from...
Read More
Dr. Midhun Malla discusses the evolving treatment landscape for advanced...
Read More
Francesco Corrado explained the research question from the oral abstract...
Read More
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, and Miriam Hobbs,...
Read More
Nayda Bidikian discusses the oral abstract she presented at ASH...
Read More
Explore how using CAR-T cell therapy earlier in treatment may...
Read More
Daniela Molena, MD, of the Memorial Sloan Kettering Cancer Center,...
Read More
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, and Miriam Hobbs,...
Read More©2026 Oncology Matrix. All Rights Reserved.
